-
1 Comment
Aquestive Therapeutics, Inc is currently in a long term downtrend where the price is trading 30.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.8.
Aquestive Therapeutics, Inc's total revenue sank by 56.5% to $7M since the same quarter in the previous year.
Its net income has dropped by 61.2% to $-20M since the same quarter in the previous year.
Finally, its free cash flow fell by 29.0% to $-14M since the same quarter in the previous year.
Based on the above factors, Aquestive Therapeutics, Inc gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US03843E1047 |
| Target Price | 9.8611 |
|---|---|
| Beta | 2.02 |
| Market Cap | 282M |
| PE Ratio | None |
| Dividend Yield | None |
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AQST using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
